Generation of Allo-Compatible T Cells Through Engineered Protein Competition
Time: 10:00 am
day: Day Two
Details:
- Selective replacement of αβTCR surface expression reduces the requirement for
gene editing of allogeneic cell therapies - Highly potent tumor targeting by αβT cells expressing specific γδTCRs (TEG)
- Broadly applicable strategy for building allogeneic T cell platforms that retain
native recognition and signaling properties - Compatibility with both DNA- and RNA-level editing
